|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Sutro_Biopharma
|
|
gptkbp:CEO
|
Liz_Barrett
|
|
gptkbp:clinicalTrials
|
Phase 3 trials
UGN-102
UGN-201
UGN-301
|
|
gptkbp:collaborations
|
gptkb:Johns_Hopkins_University
gptkb:University_of_California,_San_Francisco
|
|
gptkbp:employeeCount
|
50-100
|
|
gptkbp:financials
|
publicly traded
|
|
gptkbp:focus
|
uro-oncology
|
|
gptkbp:founded
|
2010
|
|
gptkbp:headquarters
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
UroGen Pharma
|
|
gptkbp:investmentFocus
|
available
|
|
gptkbp:leadership
|
board of directors
scientific advisory board
|
|
gptkbp:market
|
approximately $200 million
|
|
gptkbp:partnerships
|
gptkb:GSK
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Eisai
Novartis
Sanofi
AbbVie
Celgene
Takeda
Regeneron
|
|
gptkbp:patentType
|
UGN-101_for_low-grade_upper_tract_urothelial_carcinoma
|
|
gptkbp:products
|
gptkb:UGN-101
URO-902
|
|
gptkbp:researchFocus
|
kidney cancer
bladder cancer
urothelial carcinoma
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.urogen.com
|